2',4'-Dihydroxychalcone

2',4'-Dihydroxychalcone

SCHEMBL25200440

O=C(/C=C\c1ccccc1)c1ccc(O)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 1.00
CYP3A4 P08684 5/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
HPGD P15428 4/20 1.00
ALOX15 P16050 4/20 1.00
MAPK1 P28482 4/20 1.00
HSD17B10 Q99714 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
ALDH1A1 P00352 3/20 1.00
KDM4E B2RXH2 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
THRB P10828 1/20 1.00
CYP2C19 P33261 3/20 0.81
NFKB1 P19838 3/20 0.81
LMNA P02545 3/20 0.81
TP53 P04637 3/20 0.81
CYP2C9 P11712 2/20 0.81
AKR1B1 P15121 2/20 0.81
CHRNA7 P36544 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2',4'-Dihydroxychalcone SCHEMBL1411695 1.00 MAPT (1.00) MAPTCYP3A4MEN1KMT2AHPGD
2',4'-Dihydroxychalcone SCHEMBL127341 1.00 MAPT (1.00) MAPTCYP3A4MEN1KMT2AHPGD
Isoliquiritigenin SCHEMBL9448612 0.93 CYP3A4 (0.86) MAPTCYP3A4MEN1KMT2AHPGD
Isoliquiritigenin SCHEMBL9448617 0.93 CYP3A4 (0.86) MAPTCYP3A4MEN1KMT2AHPGD
SCHEMBL25208375 0.91 MEN1 (0.96) MAPTCYP3A4MEN1KMT2AHPGD
Isoliquiritigenin SCHEMBL1519061 0.91 CYP3A4 (0.83) MAPTCYP3A4MEN1KMT2AHPGD
SCHEMBL25194934 0.91 CYP3A4 (0.83) MAPTCYP3A4MEN1KMT2AHPGD
SCHEMBL25195193 0.90 MEN1 (0.82) MAPTCYP3A4MEN1KMT2AHPGD
SCHEMBL28093997 0.90 MEN1 (0.82) MAPTCYP3A4MEN1KMT2AHPGD
Isoliquiritigenin SCHEMBL10408923 0.90 CYP3A4 (1.00) MAPTCYP3A4MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885CYP3A4 928/4885MEN1 3367/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885CYP3A4 1589/4885MEN1 2457/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885CYP3A4 1589/4885MEN1 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.